Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors

ABSTRACT Resistance to antivirals is a complex and dynamic phenomenon that involves more mutations than are currently known. Here, we characterize 10 additional mutations (L74V, K101Q, I135M/T, V179I, H221Y, K223E/Q, and L228H/R) in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase which are involved in the regulation of resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs). These mutations are strongly associated with NNRTI failure and strongly correlate with the classical NNRTI resistance mutations in a data set of 1,904 HIV-1 B-subtype pol sequences from 758 drug-naïve patients, 592 nucleoside reverse transcriptase inhibitor (NRTI)-treated but NNRTI-naïve patients, and 554 patients treated with both NRTIs and NNRTIs. In particular, L74V and H221Y, positively correlated with Y181C, were associated with an increase in Y181C-mediated resistance to nevirapine, while I135M/T mutations, positively correlated with K103N, were associated with an increase in K103N-mediated resistance to efavirenz. In addition, the presence of the I135T polymorphism in NNRTI-naïve patients significantly correlated with the appearance of K103N in cases of NNRTI failure, suggesting that I135T may represent a crucial determinant of NNRTI resistance evolution. Molecular dynamics simulations show that I135T can contribute to the stabilization of the K103N-induced closure of the NNRTI binding pocket by reducing the distance and increasing the number of hydrogen bonds between 103N and 188Y. H221Y also showed negative correlations with type 2 thymidine analogue mutations (TAM2s); its copresence with the TAM2s was associated with a higher level of zidovudine susceptibility. Our study reinforces the complexity of NNRTI resistance and the significant interplay between NRTI- and NNRTI-selected mutations. Mutations beyond those currently known to confer resistance should be considered for a better prediction of clinical response to reverse transcriptase inhibitors and for the development of more efficient new-generation NNRTIs.

[1]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[2]  R. Shafer,et al.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.

[3]  C. Dykes,et al.  Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. , 2006, Virology.

[4]  Deenan Pillay,et al.  Update of the drug resistance mutations in HIV-1: Fall 2006. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[5]  Thomas Lengauer,et al.  Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors , 2006, Journal of Virology.

[6]  J. Mellors,et al.  Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors , 2006, AIDS.

[7]  U Helena Danielson,et al.  Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. , 2006, Journal of medicinal chemistry.

[8]  S. Lo Caputo,et al.  Impact of unreported HIV‐1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non‐nucleoside inhibitors , 2006, Journal of medical virology.

[9]  R. Pauwels,et al.  TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments , 2005, Journal of Virology.

[10]  Thomas Lengauer,et al.  Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking , 2005, PKDD.

[11]  Amalio Telenti,et al.  Update of the drug resistance mutations in HIV-1: Fall 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[12]  F. Ceccherini‐Silberstein,et al.  High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations , 2005, Journal of Virology.

[13]  Tommy F. Liu,et al.  HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. , 2005, The Journal of infectious diseases.

[14]  D. Katzenstein,et al.  Nonnucleoside Reverse Transcriptase Inhibitor Phenotypic Hypersusceptibility Can Be Demonstrated in Different Assays , 2005, Journal of acquired immune deficiency syndromes.

[15]  Chris Oostenbrink,et al.  A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force‐field parameter sets 53A5 and 53A6 , 2004, J. Comput. Chem..

[16]  Ronald J Bosch,et al.  Genetic correlates of efavirenz hypersusceptibility , 2004, AIDS.

[17]  F. Ceccherini‐Silberstein,et al.  Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure , 2004, AIDS.

[18]  M. Wainberg,et al.  HIV-1 subtype distribution and the problem of drug resistance , 2004, AIDS.

[19]  J. Balzarini,et al.  Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. , 2004, Current topics in medicinal chemistry.

[20]  Francesca Ceccherini-Silberstein,et al.  Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. , 2004, The Journal of infectious diseases.

[21]  Christopher J. Lee,et al.  Positive Selection Detection in 40,000 HumanImmunodeficiency Virus (HIV) Type 1 Sequences Automatically IdentifiesDrug Resistance and Positive Fitness Mutations in HIV Proteaseand ReverseTranscriptase , 2004, Journal of Virology.

[22]  E. De Clercq,et al.  Antivirals and antiviral strategies. , 2004, Nature reviews. Microbiology.

[23]  B. Canard,et al.  The Y181C Substitution in 3′-Azido-3′-deoxythymidine-resistant Human Immunodeficiency Virus, Type 1, Reverse Transcriptase Suppresses the ATP-mediated Repair of the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated Primer* , 2003, Journal of Biological Chemistry.

[24]  Thomas Lengauer,et al.  Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes , 2003, Nucleic Acids Res..

[25]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[26]  Thomas D. Wu,et al.  Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors , 2003, AIDS.

[27]  C. Moore,et al.  Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level , 2002, Science.

[28]  Robert W. Shafer,et al.  Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.

[29]  P Pezzotti,et al.  Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. , 2001, The Journal of infectious diseases.

[30]  D I Stuart,et al.  Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. , 2001, Journal of molecular biology.

[31]  A. D. Clark,et al.  The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. , 2001, Journal of molecular biology.

[32]  R. Esnouf,et al.  Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype , 2001, AIDS.

[33]  D. Richman,et al.  Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid Sites , 2000, Journal of Virology.

[34]  L. Bacheler,et al.  Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[35]  N. Sluis-Cremer,et al.  Inhibitors of HIV- I reverse transcriptase , 2000 .

[36]  N. Sluis-Cremer,et al.  Inhibitors of HIV-1 reverse transcriptase. , 2000, Advances in pharmacology.

[37]  B. Schmidt,et al.  Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. , 1999, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[38]  M A Wainberg,et al.  HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. , 1999, Archives of biochemistry and biophysics.

[39]  P. Boyer,et al.  A Mutation at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Interacts with Mutations at Positions 74 and 75 via the Template Primer , 1998, Antimicrobial Agents and Chemotherapy.

[40]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[41]  A. D. De Groot,et al.  An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. , 1997, AIDS research and human retroviruses.

[42]  S. Goff,et al.  Reverse Transcriptase and the Generation of Retroviral DNA , 1997 .

[43]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[44]  E. Arnold,et al.  Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[46]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[47]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[48]  J. Lebowitz,et al.  Human immunodeficiency virus‐1 reverse transcriptase heterodimer stability , 1994, Protein science : a publication of the Protein Society.

[49]  B. Larder,et al.  Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. , 1994, The Journal of general virology.

[50]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[51]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[52]  A. Hope.  A Simplified Monte Carlo Significance Test Procedure , 1968 .